Wolf Group Capital Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $4.23M | Sell |
37,712
-5,086
| -12% | -$525K | 1.42% | 17 |
|
|
2024
Q4 | $3.3M | Hold |
42,798
| – | – | 1.6% | 18 |
|
|
2024
Q3 | $3.3M | Buy |
42,798
+1,552
| +4% | +$118K | 1.57% | 19 |
|
|
2024
Q2 | $2.83M | Sell |
41,246
-1,552
| -4% | -$104K | 1.11% | 25 |
|
|
2024
Q1 | $3.3M | Hold |
42,798
| – | – | 1.57% | 19 |
|
|
2023
Q4 | $3.3M | Sell |
42,798
-18
| -0% | -$1.4K | 1.56% | 19 |
|
|
2023
Q3 | $3.21M | Buy |
42,816
+18
| +0% | +$1.38K | 1.52% | 19 |
|
|
2023
Q2 | $3.26M | Hold |
42,798
| – | – | 1.63% | 18 |
|
|
2023
Q1 | $3.55M | Hold |
42,798
| – | – | 1.77% | 15 |
|
|
2022
Q4 | $3.67M | Buy |
42,798
+26
| +0.1% | +$2.06K | 1.73% | 15 |
|
|
2022
Q3 | $2.64M | Hold |
42,772
| – | – | 1.45% | 22 |
|
|
2022
Q2 | $2.64M | Buy |
42,772
+15
| +0% | +$929 | 1.37% | 23 |
|
|
2022
Q1 | $2.54M | Sell |
42,757
-85,514
| -67% | -$5.47M | 1.3% | 24 |
|
|
2021
Q4 | $9.31M | Buy |
128,271
+85,514
| +200% | +$5.89M | 1.52% | 18 |
|
|
2021
Q3 | $2.99M | Hold |
42,757
| – | – | 1.63% | 18 |
|
|
2021
Q2 | $2.94M | Hold |
42,757
| – | – | 1.58% | 17 |
|
|
2021
Q1 | $2.76M | Hold |
42,757
| – | – | 1.59% | 18 |
|
|
2020
Q4 | $2.49M | Sell |
42,757
-200
| -0.5% | -$12.1K | 1.54% | 18 |
|
|
2020
Q3 | $2.71M | Sell |
42,957
-550
| -1% | -$38.1K | 1.89% | 12 |
|
|
2020
Q2 | $3.35M | Sell |
43,507
-590
| -1% | -$45.2K | 2.49% | 9 |
|
|
2020
Q1 | $3.3M | Sell |
44,097
-15,484
| -26% | -$1.07M | 2.75% | 8 |
|
|
2019
Q4 | $3.87M | Sell |
59,581
-3,748
| -6% | -$244K | 2.54% | 10 |
|
|
2019
Q3 | $4.01M | Sell |
63,329
-6,736
| -10% | -$440K | 2.76% | 10 |
|
|
2019
Q2 | $4.73M | Sell |
70,065
-1,221
| -2% | -$80.3K | 3.28% | 6 |
|
|
2019
Q1 | $4.63M | Sell |
71,286
-53
| -0.1% | -$3.52K | 3.18% | 6 |
|
|
2018
Q4 | $4.46M | Sell |
71,339
-1,162
| -2% | -$81.2K | 3.32% | 5 |
|
|
2018
Q3 | $5.6M | Sell |
72,501
-2,982
| -4% | -$225K | 3.66% | 3 |
|
|
2018
Q2 | $5.35M | Sell |
75,483
-3,766
| -5% | -$266K | 3.48% | 4 |
|
|
2018
Q1 | $5.97M | Sell |
79,249
-2,045
| -3% | -$163K | 3.96% | 3 |
|
|
2017
Q4 | $5.82M | Sell |
81,294
-2,026
| -2% | -$154K | 3.62% | 3 |
|
|
2017
Q3 | $6.66M | Sell |
83,320
-4,715
| -5% | -$361K | 4.63% | 1 |
|
|
2017
Q2 | $6.23M | Sell |
88,035
-3,927
| -4% | -$261K | 4.79% | 1 |
|
|
2017
Q1 | $6.25M | Sell |
91,962
-1,161
| -1% | -$81.6K | 4.1% | 2 |
|
|
2016
Q4 | $6.67M | Sell |
93,123
-5,319
| -5% | -$395K | 4.48% | 1 |
|
|
2016
Q3 | $7.79M | Buy |
98,442
+61,395
| +166% | +$4.99M | 5.43% | 1 |
|
|
2016
Q2 | $3.09M | Sell |
37,047
-1,719
| -4% | -$153K | 2.28% | 10 |
|
|
2016
Q1 | $3.56M | Buy |
38,766
+248
| +0.6% | +$22.4K | 2.68% | 2 |
|
|
2015
Q4 | $3.9M | Buy |
38,518
+5,911
| +18% | +$615K | 2.9% | 1 |
|
|
2015
Q3 | $3.2M | Sell |
32,607
-676
| -2% | -$75.1K | 2.57% | 4 |
|
|
2015
Q2 | $3.9M | Sell |
33,283
-208
| -0.6% | -$22.7K | 2.59% | 4 |
|
|
2015
Q1 | $3.29M | Buy |
33,491
+586
| +2% | +$59.5K | 2.26% | 5 |
|
|
2014
Q4 | $3.1M | Sell |
32,905
-1,290
| -4% | -$133K | 2.25% | 6 |
|
|
2014
Q3 | $3.64M | Sell |
34,195
-3,962
| -10% | -$388K | 2.72% | 5 |
|
|
2014
Q2 | $3.16M | Buy |
38,157
+1,045
| +3% | +$81.3K | 2.3% | 5 |
|
|
2014
Q1 | $2.63M | Sell |
37,112
-860
| -2% | -$67.4K | 2.03% | 10 |
|
|
2013
Q4 | $2.82M | Buy |
+37,972
| New | +$2.64M | 2.27% | 7 |
|
Other funds holding GILD
Wolf Group Capital Advisors's GILD Position: Q1 2025 in Review
Wolf Group Capital Advisors reduced its Gilead Sciences (GILD) stake by 12% in Q1 2025, selling an estimated $525K and leaving 37,712 shares worth $4.23M. The position accounts for 1.42% of the portfolio, ranked #17.
Wolf Group Capital Advisors first reported a position in GILD in Q4 2013 and has held it in 46 quarters since. The position peaked at $9.31M in Q4 2021. 2,014 funds tracked by Wall St. Rank hold GILD as of Q1 2025.
- Wolf Group Capital Advisors held 37,712 shares of Gilead Sciences worth $4.23M as of Q1 2025.
- Wolf Group Capital Advisors sold 5,086 Gilead Sciences shares in Q1 2025, an estimated $525K.
- Gilead Sciences made up 1.42% of Wolf Group Capital Advisors's portfolio in Q1 2025, its #17 holding.
- Wolf Group Capital Advisors first reported a position in Gilead Sciences in Q4 2013 and has held it in 46 quarters since.
- Wolf Group Capital Advisors's Gilead Sciences position peaked at $9.31M in Q4 2021.
- 2,014 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.
Based on Wolf Group Capital Advisors's 13F filing for Q1 2025, filed 18 Apr 2025.